SPC59
Samsetning af rilpivirin hýdróklóríð og hvert meðferðarfræðilega jafngilt form þess sem er verndað af grunneinkaleyfinu, og tenófóvír, einkum tenófóvír tvísópoxil fúmarat
Status:
VeittApplication date:
25.5.2012Application published:
15.6.2012Grant published:
15.10.2014
Max expiry date:
27.11.2026Next due date:
30.9.2026Medicine name:
EvipleraMedicine for children:
No
Timeline
Today
25.5.2012Application
15.6.2012Publication
15.10.2014Registration
1.9.2026Expires
Marketing license
IS authorization number:
EU/1/11/737/001-002Date:
14.12.2011
Foreign authorization number:
EU/1/11/737/001-002Date:
28.11.2011
Owner
Name:
Janssen Pharmaceutica NVAddress:
Turnhoutseweg 30, Beerse BE
Agent
Name:
Budde Schou A/SAddress:
Dronningens Tværgade 30, 1302 Copenhagen K
Patent
Number:
EP1632232
Annual fees
Number
Paid
Expires
Payer
Number: 1
Paid: 15.8.2025
Expires: 1.9.2026
Payer: Árnason Faktor ehf.